HealthLynked Corp. (OTCQB: HLYK), a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, has selected DRCARE247 as its telemedicine partner. The move, announced by HealthLynked (OTCQB: HLYK), will integrate virtual care directly into the HealthLynked mobile application and website, enabling users to transition from AI-driven health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform.
The significance of this partnership lies in its potential to close a critical gap in digital healthcare. Currently, many patients navigate a fragmented landscape: they may use one app for symptom checking, another for finding a doctor, and yet another for a telehealth visit. By embedding telemedicine into its existing ecosystem, HealthLynked aims to create a continuous, user-friendly journey. This could increase patient engagement, improve adherence to care plans, and ultimately lead to better health outcomes. For providers, the integrated platform may reduce administrative friction and enhance care coordination, aligning with the broader industry shift toward value-based care.
HealthLynked expects to begin launching the integrated telemedicine platform in selected geographic regions over the next three months, followed by expansion into additional U.S. markets, subject to provider availability and applicable state requirements. The integration is expected to work alongside the company’s AI-powered patient assistant and, where clinically appropriate and permitted, may include prescription management as part of virtual consultations. This suggests that HealthLynked is not merely adding a video call feature but is building a more holistic virtual care service that could handle a range of patient needs remotely.
The timing is notable. Telehealth adoption surged during the pandemic, but many standalone solutions have struggled with retention. By weaving telemedicine into a platform that already manages medical records and leverages AI for personalized insights, HealthLynked may be better positioned to retain users and demonstrate measurable value. The company’s cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records into one secure, accessible location. With AI-driven insights, integrated telehealth services, and intelligent patient engagement tools, HealthLynked empowers patients and providers to coordinate care more effectively while delivering savings on prescriptions and healthcare services.
For investors, the partnership signals progress in HealthLynked’s strategy to become a one-stop shop for digital health. The company supports enterprise partnerships, offering scalable solutions to healthcare networks, employers, insurers, accountable care organizations, and digital health innovators. If successful, the DRCARE247 integration could make HealthLynked’s offering more attractive to these potential partners, opening new revenue streams and strengthening its competitive moat. The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYLK, and the full press release can be viewed at https://ibn.fm/HVq1Y.
BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
